| Literature DB >> 34810179 |
Julie C Lauffenburger1,2, Nancy Haff3,2, Marie E McDonnell4, Daniel H Solomon5, Elliott M Antman6, Robert J Glynn3,7, Niteesh K Choudhry3,2.
Abstract
OBJECTIVE: Long-term adherence to evidence-based medications in cardiometabolic diseases remains poor, despite extensive efforts to develop and test interventions and deploy clinician performance incentives. The limited success of interventions may be due to ignored factors such as patients' experience of medication-taking. Despite being potentially addressable by clinicians, these factors have not been sufficiently explored, which is particularly important as patients use increasing numbers of medications. The aim is to explore patient perspectives on medication-taking, medication properties that are barriers to adherence, and coping strategies for their medication regimen.Entities:
Keywords: cardiology; diabetes & endocrinology; public health; qualitative research; therapeutics
Mesh:
Substances:
Year: 2021 PMID: 34810179 PMCID: PMC8609926 DOI: 10.1136/bmjopen-2020-046860
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Characteristics of participants
| Participant identifier | Age (years) | Chronic condition of interest |
| P1 | 62 | Diabetes, hyperlipidaemia |
| P2 | 36 | Diabetes |
| P3 | 52 | Diabetes, hyperlipidaemia, hypertension |
| P4 | 70 | Diabetes, hyperlipidaemia |
| P5 | 66 | Diabetes, hyperlipidaemia, hypertension |
| P6 | 84 | Hypertension, hyperlipidaemia |
| P7 | 62 | Diabetes, hyperlipidaemia, hypertension |
| P8 | 31 | Diabetes |
| P9 | 45 | Diabetes, hypertension |
| P10 | 65 | Diabetes, hyperlipidaemia, hypertension |
| P11 | 61 | Diabetes, hyperlipidaemia, hypertension |
| P12 | 24 | Diabetes, hypertension |
| P13 | 22 | Diabetes |
| P14 | 58 | Hypertension |
| P15 | 20 | Hypertension |
| P16 | 70 | Diabetes |
| P17 | 57 | Diabetes, hypertension |
| P18 | 55 | Diabetes, hyperlipidaemia |
| P19 | 44 | Hyperlipidaemia, hypertension |
| P20 | 73 | Hyperlipidaemia, hypertension |
| P21 | 43 | Diabetes, hypertension |
| P22 | 76 | Diabetes, hyperlipidaemia, hypertension |
| P23 | 40 | Diabetes, hyperlipidaemia, hypertension |
| P24 | 58 | Hyperlipidaemia, hypertension |
| P25 | >89 | Hyperlipidaemia, hypertension |
| P26 | 74 | Hyperlipidaemia, hypertension |
Summary of key themes
| Theme | Key takeaways |
| (1) Medication-taking viewed as a highly inconvenient action |
Annoyance at and struggling to take medications Medication-taking is viewed as a process |
| (2) Negative implications because of inconvenience or illness perceptions |
Dismay of need for lifelong use Feelings of judgement and stigma by others |
| (3) Actual regimens can deviate substantially from prescribed regimens |
Combining doses intended to be at separate times Taking medications later than prescribed Taking additional medications to counteract lifestyle Forgetting to take doses altogether |
| (4) Certain medication properties may contribute to adherence deviations |
Size of medications (too large or too small) Smell or taste are detractors Colour of medications in combination with others |
| (5) Development of numerous coping strategies to overcome barriers |
Relying on colours or imprints for pill identification Planning extra time to take medications Creating ‘cues’ to take medications Leveraging low-tech ways of transporting doses |
| (6) Suggestions to make medication-taking easier |
Reduce medication costs Simpler regimens (once weekly or daily) Create distinguishing features across medications, such as colouring or usable imprints Enable chewable or liquid versions for palatability |